Home » Stocks » OSUR

OraSure Technologies, Inc. (OSUR)

Stock Price: $10.01 USD 0.00 (0.00%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $10.40 +0.39 (3.90%) Apr 16, 7:24 PM
Market Cap 727.19M
Revenue (ttm) 171.72M
Net Income (ttm) -14.92M
Shares Out 67.51M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $10.01
Previous Close $10.01
Change ($) 0.00
Change (%) 0.00%
Day's Open 10.04
Day's Range 9.70 - 10.10
Day's Volume 821,293
52-Week Range 9.46 - 19.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

OraSure Technologies Inc (NASDAQ: OSUR) has submitted an application to the FDA seeking Emergency Use Authorization (EUA) for its COVID-19 rapid antigen test for both Prescription Home Use and Professio...

2 weeks ago - Benzinga

Tests designed to detect active COVID-19 infection with a simple, easy-to-use workflow Tests designed to detect active COVID-19 infection with a simple, easy-to-use workflow

2 weeks ago - GlobeNewsWire

OraSure (OSUR) delivered earnings and revenue surprises of -57.14% and 7.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Full-Year 2020 Net Revenues of $172 Million Increased 11% Year-Over-Year, Driven by $50 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing

1 month ago - GlobeNewsWire

BETHLEHEM, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and ana...

1 month ago - GlobeNewsWire

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

BETHLEHEM, Pa., Feb. 18, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 fourth quarter financial results and certain ...

2 months ago - GlobeNewsWire

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

This is the Eighth EUA to Include a Self-Collection Device from DNA Genotek This is the Eighth EUA to Include a Self-Collection Device from DNA Genotek

2 months ago - GlobeNewsWire

OTTAWA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical ser...

2 months ago - GlobeNewsWire

BETHLEHEM, Pa., Jan. 26, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analyt...

2 months ago - GlobeNewsWire

BETHLEHEM, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analyt...

2 months ago - GlobeNewsWire

OraSure: Well Positioned Ex-Covid, Sell Side Missing The Organic Growth Drivers

3 months ago - Seeking Alpha

BETHLEHEM, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a...

3 months ago - GlobeNewsWire

BETHLEHEM, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and ana...

3 months ago - GlobeNewsWire

OTTAWA, Dec. 23, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical ser...

3 months ago - GlobeNewsWire

BETHLEHEM, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that the U.S. Foo...

3 months ago - GlobeNewsWire

BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen ...

4 months ago - GlobeNewsWire

BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in the fight against HIV, today announced its plans to commemorate World AIDS Day. On Tuesday, Dec. ...

4 months ago - GlobeNewsWire

BETHLEHEM, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and ana...

5 months ago - GlobeNewsWire

A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance. The post Stock Upgrades: Orasure Technologies Shows Rising Relative Strength appeared first on Investor...

5 months ago - Investors Business Daily

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

OraSure (OSUR) delivered earnings and revenue surprises of 114.29% and 11.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Net T hird Q uarter R evenues of $ 48.0 M illion Increased 33 % Year-Over-Year, D riven by $ 18 . 4 M illion in S ales of O ral F luid C ollection D evices for COVID-19 M olecular T esting

5 months ago - GlobeNewsWire

Second FDA EUA for the Subsidiary's Saliva Collection Devices Second FDA EUA for the Subsidiary's Saliva Collection Devices

5 months ago - GlobeNewsWire

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

OraSure receives emergency use authorization for OMNIgene. Keros Therapeutics initiates Phase 2 clinical trial for Myelodysplastic Syndromes.

5 months ago - Seeking Alpha

BETHLEHEM, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 third quarter financial results and certain b...

5 months ago - GlobeNewsWire

The FDA granted Emergency Use Authorization for the company's at-home saliva collection device for coronavirus testing.

5 months ago - The Motley Fool

OraSure Technologies (OSUR) is in the news Monday after announcing approval from the FDA for one of its devices sent OSUR stock soaring. The post OraSure Technologies News: Why OSUR Stock Is Surging 13%...

5 months ago - InvestorPlace

Shares of OraSure Technologies, Inc. (NASDAQ: OSUR) were advancing strongly Monday after the diagnostic company said its DNA Genotek subsidiary's saliva collection device used in COVID-19 testing has be...

5 months ago - Benzinga

OraSure Technologies Inc. (NASDAQ: OSUR) shares jumped to start off the week after the company announced an update from the U.S.

5 months ago - 24/7 Wall Street

BETHLEHEM, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analyt...

6 months ago - GlobeNewsWire

Investors need to pay close attention to OraSure (OSUR) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

BETHLEHEM, Pa., Sept. 24, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and ana...

6 months ago - GlobeNewsWire

A prominent Harvard epidemiologist and expert in disease testing thinks a cheap, daily, do-it-yourself test can be as effective as a vaccine at cutting coronavirus transmission, according to an article ...

7 months ago - GuruFocus

BETHLEHEM, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and ana...

7 months ago - GlobeNewsWire

BETHLEHEM, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and a...

7 months ago - GlobeNewsWire

A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance. The post Stocks With Rising Relative Price Strength: Orasure Technologies appeared first on Investor's...

8 months ago - Investors Business Daily

OraSure Technologies, Inc. (OSUR) CEO Steve Tang on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

OraSure (OSUR) delivered earnings and revenue surprises of -77.78% and -14.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

BETHLEHEM, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and anal...

8 months ago - GlobeNewsWire

BETHLEHEM, Pa., July 31, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and anal...

8 months ago - GlobeNewsWire

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

2020 Second Quarter Earnings Conference Call Wednesday, August 5, 2020, 5:00 p.m. ET

8 months ago - GlobeNewsWire

MORRISVILLE, N.C., June 17, 2020 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to brin...

10 months ago - PRNewsWire

OTTAWA, June 17, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical s...

10 months ago - GlobeNewsWire

BETHLEHEM, Pa., June 10, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analy...

10 months ago - GlobeNewsWire

The number of EUAs utilizing OraSure’s saliva collection products continues to grow The number of EUAs utilizing OraSure’s saliva collection products continues to grow

10 months ago - GlobeNewsWire

BETHLEHEM, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the full exercise by the underwriters of their option to purcha...

10 months ago - GlobeNewsWire

About OSUR

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Nov 12, 1986
CEO
Stephen Tang
Employees
570
Stock Exchange
NASDAQ
Ticker Symbol
OSUR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is 17.00, which is an increase of 69.83% from the latest price.

Price Target
$17.00
(69.83% upside)
Analyst Consensus: Buy